OWC Pharmaceutical Research Corp. aspires to realize the potential of medical cannabis research and develops medicinal products, specifically designed to improve the lives of millions.

We fuse the freshness and the visionary approach of an innovative company with the wisdom and the knowledge of experienced players in the cannabis-based products market, by incorporating cutting-edge research, proven global experience and unprecedented professionalism of our people.

Nasal Spray

OWC is developing a new generation, nano-particular, nasal spray – a new mode of delivery that will offer a more efficient treatment for diverse Central Nervous System related syndromes. This innovative nasal spray is designed to enable the absorption of the pharmaceutical active directly to the CNS through the olfactory system and thus provide passage across the blood-brain barrier, without passage through the circulatory system.

Sublingual Disintegrating Tablet

OWC has developed a cannabinoid-enriched sublingual disintegrating tablet that will offer an alternative to smoking and inhalation, allowing for controlled, consistent dosing and diligent compliance to medical regimens. It will potentially offer quick pain and other symptomatic relief, as sublingual absorption provides a direct route for cannabis to enter more rapidly into the blood system through the oral mucosal tissue.

Research and Development

Headquartered in Israel, OWC R&D is focused on discovering, developing and commercializing cannabis-based novel products and therapies, specifically designed for treating specific medical conditions and alleviating certain disease-associated symptoms. Development

OWC leverages its extensive network, comprising some of Israel’s leading researchers, scientists, academic and medical centers in Israel, as well as cannabis breeders and extractors, to unlock the potential of cannabis for diverse therapeutic applications. OWC research is dedicated to provide patients with the assurance that they are using products that are clinically tested, safe to use, and efficient.

New at OWC

Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.

The first ever safety study of cannabis-based topical ointment, conducted at Sheba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.

OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.